retatrutide ly3437943 phase 2 trial obesity nejm 2023 Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people Retatrutide Phase 2 NEJM Trial:

(The study has not yet been published in a peer-reviewed journal.) A comparable study hasnt been done with oral Wegovy, but Novo Nordisk, the company that manufactures the drug, believes that patients should be able to switch from the Wegovy shot without affecting their weight

It may also have the potential to improve libido in research subjects

Now its just routine

Specifically, we proposed to assign HCPCS code G2082 to APC 1512 (New TechnologyLevel 12 ($1001-$1100)) with a payment rate of $1,050.50 based on its geometric mean cost of $1,019, which was calculated using the available 558 single frequency claims from CY 2024 claims data